Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nevada Cancer Institute
With
GlaxoSmithKline
Cephalon
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must be \>/= 18 years old and able to provide consent
Must have diagnosis of CLL as defined by NCI criteria
Must be previously untreated for CLL
Must require chemotherapy
serum creatinine \<1.8 mg/dl
Bilirubin must be \</= 2 mg/d, unless secondary to tumor
Must have adequate liver function (as defined as \<2x ULN, unless related to CLL)
Performance status 0-2
Women of child bearing age must be willing to use accepted/effective method of birth control.
You may not be if
Not have received prior treatment with cytotoxic chemotherapy or immunotherapy.
Not have autoimmune hemolytic anemia or autoimmune thrombocytopenia
Not have history of corticosteroid treatment for CLL
Not have CNS disease
Not have clinically significant infections
Not have positive serology for Hepatitis B or Hepatitis C
Not have be known to be HIV positive
Not have New York Classification III or IV hear disease
Clareo Health | Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab
